Epistaxis Clinical Trial
Official title:
Nasal Intubation Using a Parker Flex-tip Endotracheal Tube With Posteriorly Facing Bevel Compared to a Nasal RAE Tube With Left Facing Bevel: A Randomized Study
The purpose of this study is to determine the degree of epistaxis following nasal intubation
with either a nasal endotracheal (RAE) tube with bevel facing left or Parker Flex-Tip
endotracheal tube with bevel facing posteriorly
The investigators hypothesize that a Parker Flex-Tip endotracheal tube when inserted with
bevel facing posteriorly during nasal intubation may reduce the incidence of epistaxis intra
and post-operatively. The investigators propose that using this style of endotracheal tube
improves patient safety and comfort and facilitates ease and success of nasal intubation.
1. Purpose
To investigate and describe the use of a Parker Flex-Tip endotracheal tube (ETT) with a
posteriorly facing bevel for nasal intubation at Vancouver Coastal Health (VCH).
The investigators wish to demonstrate that a Parker Flex-Tip ETT with a posterior
facing bevel eases ETT insertion and reduces epistaxis compared to a standard nasal RAE
endotracheal tube (RAE ETT) currently used at VCH. The investigators propose that using
this method improves performance and reduces complications of nasal intubation.
2. Hypothesis
Our hypotheses are:
- That a Parker Flex-Tip ETT with a posterior facing bevel may reduce the incidence
of epistaxis
- That a Parker Flex-Tip ETT with a posterior facing bevel may allow the
anesthesiologist to successfully nasal intubate with more ease and fewer attempts.
- That use of a Parker Flex-Tip ETT with a posterior facing bevel for nasal
intubation is acceptable to anesthesiologists and patients
3. Justification
Justification for developing a new technique Endonasal intubation is a widely performed
technique that allows administration of anesthetic during oral, dental and
maxillofacial surgeries while allowing unimpeded access to the surgical site. Nasal
intubation poses several challenges not encountered in oropharyngeal intubation. These
include advancing the endotracheal tube through the highly vascularized delicate mucosa
of the nasal passage, past protruding turbinates, and maneuvering through the sharply
angulated nasopharyx to access the trachea (Hall).
The most common complication associated with endonasal intubation is epistaxis due to
nasal abrasion, most commonly in the anterior part of the nasal septum, which can range
from mild blood tinged mucus to massive epistaxis (Tintinalli, O'Connell, Hall). The
risk of epistaxis increases with the use of excessive force, large endotracheal tube,
repeated unsuccessful attempts and abnormal pharyngeal anatomy (Hall ). Rarer
complications of nasal intubation include traumatic avulsion of the turbinates,
turbinate fracture, retro pharyngeal laceration, and bacteremia (Williams, Hall,
Dinner).
Common techniques used to reduce the risks associated with nasal intubation include the
use of vasoconstrictors in the nasal canal, lubrication of the endotracheal tube,
selection of a smaller tube, mechanical dilatation of the nasal cavity, deliberate
maneuvering of the tube during intubation (Hall). Other more complicated techniques
have included thermosoftening and using a curved tip suction catheter to help guide the
endotracheal tube (Kim, Morimoto, Wart, Seo). Overall these precautions and
interventions are complicated and often ineffective in reducing complications.
The main justification for our study is the finding from a recent study by Sugiyama .
(2014) that using a Parker Flex-Tip ETT with a bent flexible tip, and advancing with
the aid of an anterior flexed stylette with bevel facing posteriorly reduced the
incidence of epistaxis to 4% compared to 50%, with a standard ETT. In our practice the
investigators have noticed epistaxis to be present more often than not with the present
nasal RAE ETT. However, the investigators have not quantified this scientifically. This
significant reduction of epistaxis with a Parker Flex-Tip ETT, offers a simple and
effective way to enhance patient safety and improve user ease when nasal intubation is
indicated, and will improve the quality of care in our practice.
The Parker Flex-Tip in our proposed study is identical to the Parker Flex-Tip used in
the study by Sugiyama. Based on the findings by Sugiyama , the tube should allow the
ETT to curve towards the oropharynx as it approaches the curve of the nasopharynx and
therefore reduce impact and damage to the pharyngeal mucosa. Positioning the bevel to
face posteriorly will allow the tube to slide along the posterior wall and reduce the
risk of turbinate abrasion as it is advanced. The soft and curved distal tip presumably
curls inward when it is advanced past the curve and a larger surface area of the tip
comes into contact with the mucous membrane, reducing the pressure on the pharyngeal
mucosa. Overall, the investigators predict that these modifications will increase ease
of insertion and reduce the number of attempts to successful intubation, which should
improve user ease and decrease risk of pharyngeal bleeding.
The investigators aim to conduct a clinical study in 20-30 patients randomized to
either the standard nasal RAE tube currently employed in our hospital or the Parker
Flex-Tip ETT to demonstrate the feasibility of our technique in reducing endonasal
complications at VCH.
4. Objectives - Primary and Secondary
Our primary objective is to describe the incidence of epistaxis with the use of a
Parker Flex-Tip endotracheal tube with bevel facing posteriorly during nasal
intubation.
Our secondary objectives are to describe the ease of use of a Parker Flex-Tip
endotracheal tube with bevel facing posteriorly, as well as patient and operator
satisfaction with the technique.
5. Research Methods
To fulfill our objectives the investigators aim to perform a study in a clinical phase.
A. Clinical Phase:
The investigators plan to perform a clinical randomized study assessing the ease of use
and complication rate associated with of a Parker Flex-Tip ETT with a posterior facing
bevel during nasal intubation compared to a standard nasal RAE ETT.
Study Population:
Between 20 and 30 ASA physical status I or II patients undergoing oral or maxillofacial
surgery where a nasal intubation would be appropriate for surgical anesthesia.
ASA Physical Status 1 - A normal healthy patient
ASA Physical Status 2 - A patient with mild systemic disease
ASA Physical Status 3 - A patient with severe systemic disease
ASA Physical Status 4 - A patient with severe systemic disease that is a constant
threat to life
ASA Physical Status 5 - A moribund patient who is not expected to survive without the
operation.
Patients who have documented deformities that will hinder nasal intubation, patients
with a history of trauma or surgery in the area of interest, a history of epistaxis or
-coagulopathies will be excluded from the study. Opioid tolerant patients taking more
than 30 mg oral morphine equivalent will also be excluded from the study.
Randomization and Blinding:
A staff member with no clinical involvement in the study will insert the group
allocation into an opaque envelope and seal the envelope. At the induction of
anesthesia the envelope will be opened and the anesthesiologist will prepare the
assigned tracheal tube and insert it.
Patients will be randomly allocated to one of two groups differentiated by the type of
endotracheal tube used (either a standard nasal RAE endotracheal tube with the bevel
facing left or Parker Flex-Tip ET tube with bevel facing posteriorly).
Intra operative measurements will be obtained and recorded by the attending
anesthetist.
The assessment of the presence of a post operative nose bleed or nasal pain and
discomfort will be measured and recorded by an investigator who is not the attending
anesthetist for the case and who is blinded to the group allocation.
6. Interventions
Patients who are scheduled for maxillofacial surgery where nasal intubation would be
appropriate to deliver surgical anesthesia and who consent to participate will be studied. A
single experienced operator with at least 5 years of clinical anesthetic experience will
perform the clinical examination and intubation. Routine monitors will be applied and
peripheral intravenous access will be established. Oxygen will be given via face mask.
Anesthesia induction using intravenous fentanyl (2.5 mcg/kg), propofol (1-2 mg/kg) and
rocuronium (0.5-1mg/kg) will be administered for muscle relaxation. The nostril that the
patient finds easy to breathe through will be chosen for intubation. If nostril conditions
are the same on both sides the right nostril will be preferred for intubation. The tracheal
tube (internal diameter [ID] 7 mm for males or 6.0 mm for females) will be coated with
lubricating gel and gently inserted into the patients' selected nostril. Those assigned to
the Parker Flex-Tip endotracheal tube will have a curved stylette inserted in the tube
before induction and the bevel will be inserted facing posteriorly. Those assigned to the
standard nasal RAE endotracheal tube will have the bevel facing leftward. Both study groups
will have the ETT warmed and lubricated prior to insertion.
If no resistance of the either endotracheal tube during advancement into the oropharynx is
noted it will be defined as "smooth", and will be inserted into the trachea using direct
laryngoscopy. In patients assigned to the Parker Flex-Tip endotracheal tube, the stylette
will be withdrawn from the tube immediately after the tube passes through the nasopharynx
and the tube will then be advanced into the trachea by direct laryngoscopy. If resistance is
noted on insertion of either ETT it will be recorded as "impinged" and a mark will be made
on the tube corresponding to the depth of insertion into the nostril to allow the distance
between the tip of the tube and the mark to be measured. The assessment of the ease of
insertion will only be made on the first attempt, with no manipulation applied against
resistance.
The degree of epistaxis will be assessed by a blinded independent investigator immediately
post intubation and up to 5 minutes post intubation, and along with ease of insertion,
recorded. Quantity of epistaxis will be measured by swabbing the nasopharynx with a dry swab
and measuring the difference in weight gain between the dry swab and blood soaked swab.
Epistaxis will be evaluated based on the criteria established by Sugiyama . Four grades will
be used:
1. No epistaxis, no blood observed on either the surface of the tube or the posterior
pharyngeal wall
2. Mild epistaxis with blood apparent on the surface of the tube or posterior pharyngeal
wall
3. Moderate epistaxis with pooling of blood on the posterior pharyngeal wall
4. Severe epistaxis with a large amount of blood in the pharynx impeding nasotracheal
intubation and necessitating urgent orotracheal intubation
7. Study Outcome
The principal outcome is reduced epistaxis using the Parker Flex-Tip endotracheal tube when
compared to the standard nasal RAE ETT with a left facing bevel.
Secondary outcomes will include:
- Ease of tube insertion
- Number of attempts to insert tube
- Post-operative patient nasal pain (Visual Analogue Score anchored at 0= no pain & 10=
maximum pain) and satisfaction scores
- Operator assessment of procedure
8. Statistical analysis
Sample size between 20 and 30. Using the results of Sugiyama (2014) study the investigators
predict that the incidence of epistaxis will range between 50% and 4% in the RAE and Parker
Flex-Tip group respectively. Fisher's exact test determined the sample size of at least 7
per group using α = 0.05 (two sided) and a power of 80%.
Descriptive statistics will be used to analyze success rate and to present the information
gathered.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05334017 -
Xylometazoline and Cocaine for Nasal Vasoconstriction
|
Phase 4 | |
Not yet recruiting |
NCT04519463 -
The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing
|
Early Phase 1 | |
Recruiting |
NCT01886768 -
Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy
|
N/A | |
Recruiting |
NCT00390663 -
A Prospective Randomised Controlled Trial of Management of Recurrent Nosebleeds in Children
|
Phase 4 | |
Suspended |
NCT04054687 -
Intranasal TXA for Anterior Epistaxis in the Emergency Department
|
Phase 2 | |
Completed |
NCT02285634 -
The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.
|
N/A | |
Completed |
NCT01485224 -
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
|
Phase 2 | |
Completed |
NCT00793117 -
The Effect of Packing in Post Operative Management of FESS
|
Phase 4 | |
Recruiting |
NCT06259292 -
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
|
||
Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05281952 -
Medico-economic Evaluation of Management Strategies for Severe Epistaxis
|
N/A | |
Completed |
NCT03360045 -
Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis
|
Phase 4 | |
Completed |
NCT04279288 -
The Roles of Hilotherapy in the Management of Epistaxis and Nasal Fractures
|
N/A | |
Completed |
NCT03912051 -
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
|
N/A | |
Not yet recruiting |
NCT02677467 -
Correlation Between Epistaxis and Cardiovascular Disease
|
N/A | |
Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
Terminated |
NCT01051427 -
Control of Epistaxis With Surgiflo
|
N/A | |
Completed |
NCT00863356 -
Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis
|
N/A | |
Recruiting |
NCT05269849 -
Sirolimus for Nosebleeds in HHT
|
Phase 2 | |
Not yet recruiting |
NCT05343650 -
NOVAPAK Nasal Packing in Shellfish Allergic Patients
|
Phase 4 |